Compare Bristol-Myers Squibb Co (BMY) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Northrop Grumman Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.95 (market cap $116.30B), while Northrop Grumman Corporation trades at $535.81 (market cap $75.09B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NOC | |
|---|---|---|
Market Cap | $116.30B | $75.09B |
Sector | Health | Industrials |
52-Week High | $62.37 | $768.02 |
52-Week Low | $42.60 | $496.02 |
Enterprise Value | $152.24B | $89.31B |
Dividend Yield | 4.42% | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Northrop Grumman (NOC) trades at $541.82, up 0.41% with neutral technical signals. The company shows strong fundamentals with consistent earnings beats, a 10.8% net income margin, and a $96 billion backlog supporting growth. Recent news highlights expansion in defense and aerospace sectors, driven by increased government spending and new contracts.
Outlook is positive with a consensus price target of $655, indicating 21% upside. Risks include political budget shifts and execution challenges. Analyst sentiment is bullish (57% buy ratings), but investors should monitor Q2 2026 earnings due July 21 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
